ABL1 and cancer: Despite their primary use in oncology, BCR-ABL inhibitors have shown emerging promise in non-cancer indications, largely attributable to their inhibition of kinases implicated in fibrosis, neurodegeneration, immune modulation, and metabolic regulation [7].